Bayer presents new data across oncology portfolio at the 2023 ASCO Annual Meeting

Summary

Bayer continues to focus on advancing prostate cancer care from early to metastatic stage with darolutamide data in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 dichloride data in metastatic castration-resistant prostate cancer (mCRPC) / Confirming Bayer’s investment in Precision Oncology, larotrectinib data presented at ASCO demonstrate long-term efficacy and safety in patients with tropomyosin receptor kinase (TRK) fusion lung and thyroid cancer, in addition to data from investigator-initiated research in pediatric patients with newly diagnosed infantile fibrosarcoma (IFS)